Classic Kites

Main Menu

  • Home
  • Kites
  • German Loans
  • German Economy
  • Flying Kites
  • Finance Debt

Classic Kites

Header Banner

Classic Kites

  • Home
  • Kites
  • German Loans
  • German Economy
  • Flying Kites
  • Finance Debt
Kites
Home›Kites›Kite to sell drug platform and manufacturing plant to BioNTech

Kite to sell drug platform and manufacturing plant to BioNTech

By Bethany Blackford
July 20, 2021
0
0

Photo by Christiaan Cruz

Santa Monica-based biopharmaceutical company Kite will sell one of its drug platforms and a manufacturing facility in Maryland to BioNTech under a deal the two companies announced on July 19.

BioNTech, a biotechnology company based in Mainz, Germany, is best known for its partnership with Pfizer Inc. which generated one of two widely used Covid mRNA vaccines in the United States and several other countries.

Kite, which was founded by serial biotech entrepreneur Arie Belldegrun, was purchased in 2017 by Foster City-based Gilead Sciences Inc. for $ 11.9 billion.

Financial terms of the transaction between Kite and BioNTech were not disclosed; nor was a closing date.

Agreement Seeks BioNTech to Acquire Kite’s Solid Tumor Antigen T cell receptor drug platform, as well as a clinical manufacturing facility in Gaithersburg, Md., For a one-time, undisclosed initial price . This facility will provide production capacity to support clinical trials in the United States and complement BioNTech’s existing cell therapy manufacturing facility in Idar-Oberstein, Germany.

Under the agreement, all Kite employees at the Gaithersburg facility will be offered employment with BioNTech prior to the closing date.

BioNTech said in the announcement that it plans to invest more in the site, including hiring additional staff.

The deal does not include Kite’s new manufacturing facility in Frederick, Md., For the commercial production of its CAR T cell immunotherapies.

Kite CEO Christi Shaw said in the announcement that the deal allows the company to focus more on these CAR T cell therapies.

“In order to serve more patients who need cell therapy today, Kite is growing rapidly both through its global expansion and the search for new indications for our already approved CAR T therapies. This transaction will allow us to focus our energies and investments on accelerating the reach of our current CAR T cell therapies and pipeline over the medium term, ”said Shaw.

For reprint and license requests for this article, CLICK HERE.

Related posts:

  1. Myers Park kitesurfers chase the adrenaline rush in Cayuga | Lansing
  2. International Air Cushion Machine Market Pattern Analysis Report 2020 – Compak, Kite Wrapping, Shenzhen Dinglisheng Know-how – KSU
  3. ‘Ger died doing what he cherished most … flying by the sky’ – household of a tragic kite-surfer who misplaced his life off the coast of Dublin
  4. NASA gave $ 500,000 to Ohio firm to develop kite-type sensors for Venus
Tagsunited states

Recent Posts

  • Macro Snapshot – German Economy Grows in Q1; Investment banks cut China’s growth outlook
  • The kite that got away
  • Breaking the Bias in Binary – The New Indian Express
  • How Flemish broadcaster VRT became a media innovation powerhouse
  • ‘A Gaping Wound’: How a Birds of Prey movie is a warning to India’s capital | Movies

Archives

  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • July 2020
  • November 2019
  • October 2019
  • September 2019
  • July 2019

Categories

  • Finance Debt
  • Flying Kites
  • German Economy
  • German Loans
  • Kites
  • Terms and Conditions
  • Privacy Policy